Entyvio ( Vedolizumab )


Medical Evidence entyvio

Generic name : Vedolizumab.

Trade name : Entyvio.

Manufacturer information :

Entyvio is manufactured by Takeda Pharmaceuticals U.S.A., Inc.

Entyvio FDA Approval :

Entyvio first approved May 20th, 2014.

Entyvio Dosage form :

For injection: 300 mg of lyophilized entyvio (vedolizumab) in a single-use 20 mLvial.

Entyvio Indications and Usage :

Ulcerative colitis and crohn disease :

Indicated for adults with moderate-to-severe active ulcerative colitis and crohn disease who have had an inadequate response with, lost response to, or were intolerant of a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.

Indication includes

  • Inducing and maintaining clinical response.
  • Inducing and maintaining clinical remission.
  • Improving the endoscopic appearance of the mucosa.
  • Achieving corticosteroid-free remission.

Entyvio (Vedolizumab) availability in India

  • You could import this medicine against import permit on Patient Name.
  • Please contact ACT Lifesciences Private Limited for further information.